Anti-HER2 Therapy Before and After Surgery for HER2-Positive Breast Cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a targeted therapy (anti-HER2) given before and after surgery for Nigerian women with HER2-positive breast cancer. It aims to see if this treatment helps shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- Your breast cancer is HER2-positive (a protein that helps cancer grow).
- Your tumor is at least 2 centimeters (about the size of a grape) and can be seen on ultrasound.
- Your cancer is stage 2A, 2B, 3A, 3B, or 3C (has not spread to distant parts of the body).
- You have not had chemotherapy for this breast cancer before.
- If you could become pregnant, you agree to use a reliable birth control method and take a hormone-blocking medication (Zoladex) for two years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This study tests whether giving two drugs (SHR-A1811 and pertuzumab) before surgery can shrink HER2-positive breast cancer tumors. It aims to see if this combination improves treatment outcomes for patients with stage II or III disease.
This trial tests a new drug called trastuzumab rezetecan given before surgery for early-stage HER2-positive breast cancer. It's designed for patients whose cancer doesn't respond well to standard HER2-targeted treatments.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This phase 3 trial compares two pre-surgery treatment plans for people with HER2-positive invasive breast cancer that has spread to nearby lymph nodes. It aims to see which plan works better to shrink the tumor before surgery and improve outcomes.
Hear when a new Human Epidermal Growth Factor 2 Negative Carcinoma of Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.